Geron Stops Embryonic Stem Cell Trial for Spinal Cord Injury

Spine

Geron, a Menlo Park, Calif.-based medical device company, has halted the first therapy made from embryonic stem cells for spinal cord injury patients that was initiated in 2010, according to a Geron news release. The company has decided to discontinue its stem cell trial for spinal cord injury patients in an effort to focus on its oncology program. The change comes in part because of the uncertain economic climate in the United States, as eliminating efforts on the spinal cord injury program will allow the company enough resources to develop oncology drugs that are currently in Phase II clinical trials.

While the company has closed the spinal cord injury trial to future enrollment, it will continue to follow all enrolled patients and update the FDA and medical community on trial data. To this point, none of the four enrolled patients have experienced adverse effects.



Related Articles on Spinal Cord Injury:
A New Hope for Treating Spinal Cord Injury: 5 Points on InVivo Therpeutics' Technology

Restoring Function After Spinal Cord Injury With Nerve Transplant: The New Frontier

Paralyzed Patient Regains Some Motion After Electrical Spinal Cord Stimulation


Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers